FDA Accepts Supplement Application for HADLIMA by Samsung Bioepis
The FDA has accepted the supplemental application for HADLIMA (BLA761059), a biosimilar to adalimumab.
Therapeutic Area
Therapeutic area intelligence for Biosimilar with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.